CO6700825A2 - 2-oxo-y 2-tioxo-dihidroquinolinas-3-carboxamidas sustituidos como ,oduladores kcnq2/3 - Google Patents
2-oxo-y 2-tioxo-dihidroquinolinas-3-carboxamidas sustituidos como ,oduladores kcnq2/3Info
- Publication number
- CO6700825A2 CO6700825A2 CO13037611A CO13037611A CO6700825A2 CO 6700825 A2 CO6700825 A2 CO 6700825A2 CO 13037611 A CO13037611 A CO 13037611A CO 13037611 A CO13037611 A CO 13037611A CO 6700825 A2 CO6700825 A2 CO 6700825A2
- Authority
- CO
- Colombia
- Prior art keywords
- residue
- aliphatic
- thioxo
- oxo
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Quinoline Compounds (AREA)
Abstract
La presente solicitud de invención se refiere fórmula general (I)Caracterizado en que Rrepresenta un residuo C- alifático, un residuo Califático, Un residuo C- ciclo alifático no sustituido o mono- o poli-sustituido, con al menos un sustituyente seleccionado del grupo que consiste de F. CI, Br, l, NO, NH, un residuo NH(Califático), OH, un residuo O-C- alifático, OCF, SH, SCF, un residuo S-C-alifático, CF, CN, un residuo C-alifático, un residuo S-C- alifático, un residuo S(O)-C-alifático, un residuo S(=O)-O-C-alifático, o 2-oxo- y 2-tioxo-dlhldróquinolina-3-carboxamidas sustituidas con composiciones farmacéuticas que contienen estos compuestos, para uso en el tratamiento y/o profilaxis del dolor y otras patologías y/o trastornos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10008920 | 2010-08-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6700825A2 true CO6700825A2 (es) | 2013-06-28 |
Family
ID=43304979
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO13037611A CO6700825A2 (es) | 2010-08-27 | 2013-02-25 | 2-oxo-y 2-tioxo-dihidroquinolinas-3-carboxamidas sustituidos como ,oduladores kcnq2/3 |
Country Status (30)
Country | Link |
---|---|
US (1) | US8653102B2 (es) |
EP (1) | EP2609086B1 (es) |
JP (1) | JP5837934B2 (es) |
KR (1) | KR101983979B1 (es) |
CN (1) | CN103189357B (es) |
AR (1) | AR082731A1 (es) |
AU (1) | AU2011295408B2 (es) |
BR (1) | BR112013004690A2 (es) |
CA (1) | CA2809287C (es) |
CL (1) | CL2013000542A1 (es) |
CO (1) | CO6700825A2 (es) |
CY (1) | CY1116158T1 (es) |
DK (1) | DK2609086T3 (es) |
EC (1) | ECSP13012460A (es) |
ES (1) | ES2537615T3 (es) |
HK (1) | HK1185346A1 (es) |
HR (1) | HRP20150520T1 (es) |
HU (1) | HUE024870T2 (es) |
IL (1) | IL223820A (es) |
MX (1) | MX342459B (es) |
NZ (1) | NZ608697A (es) |
PE (1) | PE20140214A1 (es) |
PL (1) | PL2609086T3 (es) |
PT (1) | PT2609086E (es) |
RS (1) | RS54002B1 (es) |
RU (1) | RU2581362C2 (es) |
SI (1) | SI2609086T1 (es) |
TW (1) | TWI552750B (es) |
WO (1) | WO2012025239A1 (es) |
ZA (1) | ZA201302265B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2011295405B2 (en) * | 2010-08-27 | 2015-01-22 | Grünenthal GmbH | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators |
US9775843B2 (en) | 2012-10-11 | 2017-10-03 | Grünenthal GmbH | Treatment and/or prophylaxis of TSPO mediated diseases and/or disorders |
WO2017120355A1 (en) * | 2016-01-06 | 2017-07-13 | Teva Pharmaceutical Industries Ltd. | Dihydroquinolines and uses thereof |
SG11201905893WA (en) * | 2017-01-23 | 2019-08-27 | Cadent Therapeutics Inc | Potassium channel modulators |
MX2021004647A (es) | 2018-10-22 | 2021-08-16 | Novartis Ag | Formas cristalinas de moduladores de los canales de potasio. |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2513949A1 (de) | 1975-03-29 | 1976-10-07 | Bayer Ag | Azofarbstoffe |
DE2706977A1 (de) | 1977-02-18 | 1978-08-24 | Hoechst Ag | Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung |
FR2482596A1 (fr) | 1980-05-19 | 1981-11-20 | Roussel Uclaf | Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur procede de preparation et leur application comme medicament |
DE3111934A1 (de) | 1981-03-26 | 1982-10-07 | Bayer Ag, 5090 Leverkusen | Oel-in-wasser-emulsionen, verfahren zu deren herstellung und deren verwendung |
FR2509728A1 (fr) | 1981-07-17 | 1983-01-21 | Roussel Uclaf | Nouveaux derives de la quinoleine, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant |
DE3210063A1 (de) | 1982-03-19 | 1983-09-22 | Hoechst Ag, 6230 Frankfurt | Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
DE3211934A1 (de) | 1982-03-31 | 1983-10-13 | Hoechst Ag, 6230 Frankfurt | Salicylsaeurederivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
FR2532939A1 (fr) | 1982-09-13 | 1984-03-16 | Roussel Uclaf | Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur preparation, leur application comme medicament, les compositions les renfermant et les nouveaux intermediaires obtenus |
JP3122671B2 (ja) * | 1990-05-23 | 2001-01-09 | 協和醗酵工業株式会社 | 複素環式化合物 |
DE4032147A1 (de) | 1990-10-10 | 1992-04-16 | Bayer Ag | Verwendung von substituierten 2-mercaptonicotinsaeurederivaten zur bekaempfung von endoparasiten, neue substituierte 2-mercaptonicotinsaeurederivate und verfahren zu ihrer herstellung |
US5359365A (en) | 1991-05-24 | 1994-10-25 | Canon Kabushiki Kaisha | Moving image processing method and apparatus |
US6030983A (en) | 1993-06-04 | 2000-02-29 | Ball State University | Lavendamycin analogs, quinoline-5,8-diones and methods of using them |
US5525611A (en) | 1993-06-04 | 1996-06-11 | Behforouz; Mohammad | Lavendamycin analogs and methods of making and using them |
ATE188377T1 (de) | 1993-06-29 | 2000-01-15 | Takeda Chemical Industries Ltd | Chinoline oder chinazolin-derivate und deren verwendung zur herstellung eines medikaments für die behandlung von osteoporose |
GB9402275D0 (en) * | 1994-02-07 | 1994-03-30 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
SE9400809D0 (sv) * | 1994-03-10 | 1994-03-10 | Pharmacia Ab | New use of quinoline-3-carboxamide compounds |
EP0716077A1 (de) | 1994-12-08 | 1996-06-12 | Ciba-Geigy Ag | Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren |
WO1996026925A1 (fr) | 1995-03-01 | 1996-09-06 | Banyu Pharmaceutical Co., Ltd. | Derives de l'arylthioacetamide |
JPH08337583A (ja) * | 1995-04-13 | 1996-12-24 | Takeda Chem Ind Ltd | 複素環化合物およびその製造法 |
DE19738616A1 (de) | 1997-09-04 | 1999-03-11 | Clariant Gmbh | 4-Hydroxychinolin-3-carbonsäure-Derivate als Lichtschutzmittel |
GB9807114D0 (en) | 1998-04-02 | 1998-06-03 | Smithkline Beecham Plc | Novel process |
SE9802549D0 (sv) * | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
JP2000256323A (ja) | 1999-01-08 | 2000-09-19 | Japan Tobacco Inc | 2−オキソキノリン化合物及びその医薬用途 |
AU3033500A (en) | 1999-01-15 | 2000-08-01 | Agouron Pharmaceuticals, Inc. | Non-peptide glp-1 agonists |
WO2001010381A2 (en) | 1999-08-04 | 2001-02-15 | Icagen, Inc. | Methods for treating or preventing pain and anxiety |
EP1208085B1 (en) | 1999-08-04 | 2007-12-05 | Icagen, Inc. | Benzanilides as potassium channel openers |
US6395750B1 (en) | 1999-10-25 | 2002-05-28 | Active Biotech Ab | Drugs for the treatment of malignant tumors |
ES2330719T3 (es) * | 2000-12-28 | 2009-12-15 | SHIONOGI & CO., LTD. | Derivados de 2-piridona con afinidad para el receptor cannabinoide de tipo 2. |
JP2005507853A (ja) | 2001-02-20 | 2005-03-24 | ブリストル−マイヤーズ スクイブ カンパニー | Kcnqカリウムチャンネルモジュレーター並びに片頭痛および機構的に関連する疾患の治療におけるそれらの使用 |
HUP0303841A2 (hu) | 2001-02-20 | 2004-03-01 | Bristol-Myers Squibb Company | 2,4-Diszubsztituált-5-pirimidinkarboxamid-származékok mint KCNQ káliumcsatorna modulátorok és ezeket tartalmazó gyógyszerkészítmények és előállításuk |
US6593349B2 (en) | 2001-03-19 | 2003-07-15 | Icagen, Inc. | Bisarylamines as potassium channel openers |
WO2002081728A2 (en) | 2001-04-06 | 2002-10-17 | Smithkline Beecham Corporation | Quinoline inhibitors of hyak1 and hyak3 kinases |
MXPA05002914A (es) | 2002-09-17 | 2005-05-27 | Pharmacia Corp | Moduladores de los receptores x hepaticos aromaticos. |
WO2004026819A2 (en) | 2002-09-18 | 2004-04-01 | The Curators Of The University Of Missouri | OPIATE ANALOGS SELECTIVE FOR THE delta-OPIOID RECEPTOR |
US20040198724A1 (en) | 2002-12-23 | 2004-10-07 | Icagen, Inc. | Quinazolinones as potassium channel modulators |
EP1449841A1 (en) | 2003-02-19 | 2004-08-25 | Bayer CropScience SA | New fungicidal compounds |
EP1604983A4 (en) | 2003-03-17 | 2008-06-25 | Takeda Pharmaceutical | Receptor Antagonists |
EP1680411A2 (en) | 2003-10-08 | 2006-07-19 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups |
CA2545092C (en) | 2003-11-24 | 2010-08-17 | Pfizer Inc. | Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity |
AR048669A1 (es) | 2004-03-03 | 2006-05-17 | Syngenta Ltd | Derivados biciclicos de bisamida |
JP4054369B2 (ja) | 2004-05-04 | 2008-02-27 | ファイザー株式会社 | オルト置換アリールまたはヘテロアリールアミド化合物 |
WO2006051311A1 (en) | 2004-11-12 | 2006-05-18 | Galapagos Nv | Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes |
EP1861394A1 (en) | 2005-03-03 | 2007-12-05 | H.Lundbeck A/S | Substituted pyridine derivatives |
DE102005038947A1 (de) | 2005-05-18 | 2006-11-30 | Grünenthal GmbH | Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln |
WO2007015767A1 (en) | 2005-07-20 | 2007-02-08 | Eli Lilly And Company | Pyridine derivatives as dipeptedyl peptidase inhibitors |
CN101277939A (zh) | 2005-09-09 | 2008-10-01 | 布里斯托尔-迈尔斯斯奎布公司 | 无环ikur抑制剂 |
EP1951685A1 (en) | 2005-11-18 | 2008-08-06 | NeuroSearch A/S | Novel quinazoline derivatives and their medical use |
JP5202327B2 (ja) | 2005-12-09 | 2013-06-05 | アムジエン・インコーポレーテツド | プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用 |
CN104138634B (zh) | 2006-04-13 | 2016-09-07 | 梯瓦制药国际有限责任公司 | 递送抗偏头痛化合物的透皮方法和系统 |
US7763607B2 (en) * | 2006-04-27 | 2010-07-27 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators |
WO2007133637A2 (en) | 2006-05-10 | 2007-11-22 | Renovis, Inc. | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
JP2009542798A (ja) | 2006-07-11 | 2009-12-03 | ファイザー株式会社 | 置換n−二環式アルキル二環式カルボキシアミド化合物 |
DE602007004638D1 (de) | 2006-07-20 | 2010-03-18 | Amgen Inc | Benzoädüisoxazol-derivate als c-kit-tyrosinkinase-hemmer zur behandlung von erkrankungen im zusammenhang mit der überproduktion von histamin |
CA2658190C (en) | 2006-07-20 | 2013-01-29 | Amgen Inc. | Di-amino-substituted heterocyclic compounds and methods of use |
WO2008014307A2 (en) | 2006-07-26 | 2008-01-31 | Novartis Ag | Inhibitors of undecaprenyl pyrophosphate synthase |
US20100022589A1 (en) | 2006-07-27 | 2010-01-28 | Mccoull William | Pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase |
US20110130397A1 (en) * | 2006-09-22 | 2011-06-02 | Soongyu Choi | Pyrrolinone compounds as inhibitors of bacterial peptidyl trna hydrolase and uses thereof |
DE102006049452A1 (de) | 2006-10-17 | 2008-05-08 | Grünenthal GmbH | Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln |
JP2010512305A (ja) | 2006-10-23 | 2010-04-22 | ファイザー株式会社 | 置換フェニルメチルビシクロカルボキシアミド化合物 |
WO2008097976A1 (en) | 2007-02-09 | 2008-08-14 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 for treatment of disease |
WO2008113006A1 (en) | 2007-03-14 | 2008-09-18 | Xenon Pharmaceuticals Inc. | Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions |
US9162984B2 (en) | 2007-03-30 | 2015-10-20 | University Of Rochester | Small-molecule modulators of melanin expression |
US8563566B2 (en) | 2007-08-01 | 2013-10-22 | Valeant Pharmaceuticals International | Naphthyridine derivatives as potassium channel modulators |
BRPI0814758A2 (pt) | 2007-08-03 | 2015-03-03 | Hoffmann La Roche | Piridinacarboxamida e derivados de benzamida como ligantes taar1 |
CA2702469A1 (en) | 2007-10-19 | 2009-04-23 | Boehringer Ingelheim International Gmbh | Ccr10 antagonists |
US8119656B2 (en) * | 2007-12-07 | 2012-02-21 | The Board Of Regents Of The University Of Texas System | Inhibitors of the influenza virus non-structural 1 protein |
AU2008345225A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
US8513295B2 (en) | 2008-09-23 | 2013-08-20 | Georgetown University | Viral and fungal inhibitors |
DK2350093T3 (da) | 2008-10-24 | 2012-11-12 | Gruenenthal Gmbh | Substituerede 4,5,6,7-tetrahydrothienopyridiner som KCNQ2/3-modulatorer til behandling af smerte, epilepsi og urininkontinens. |
US8367700B2 (en) | 2008-12-17 | 2013-02-05 | Gruenenthal Gmbh | Substituted 4-(1.2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators |
WO2010094645A1 (en) | 2009-02-17 | 2010-08-26 | Neurosearch A/S | Substituted pyridine derivatives and their medical use |
WO2010094644A1 (en) | 2009-02-17 | 2010-08-26 | Neurosearch A/S | Substituted pyridine derivatives and their medical use |
TWI504395B (zh) | 2009-03-10 | 2015-10-21 | Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier | |
WO2010102778A2 (de) | 2009-03-10 | 2010-09-16 | Grünenthal GmbH | Substituierte 3-aminoisoxazolopyridine als kcnq2/3 modulatoren |
TWI475020B (zh) | 2009-03-12 | 2015-03-01 | The substituted nicotine amide as a KCNQ2 / 3 modifier | |
TW201038565A (en) | 2009-03-12 | 2010-11-01 | Gruenenthal Gmbh | Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators |
TWI461197B (zh) | 2009-03-12 | 2014-11-21 | 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier | |
AU2011295407B2 (en) | 2010-08-27 | 2016-01-21 | Grunenthal Gmbh | Substituted quinoline-3-carboxamides as KCNQ2/3 modulators |
AU2011295405B2 (en) * | 2010-08-27 | 2015-01-22 | Grünenthal GmbH | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators |
-
2011
- 2011-08-26 PE PE2013000317A patent/PE20140214A1/es active IP Right Grant
- 2011-08-26 TW TW100130611A patent/TWI552750B/zh not_active IP Right Cessation
- 2011-08-26 US US13/218,579 patent/US8653102B2/en not_active Expired - Fee Related
- 2011-08-26 NZ NZ608697A patent/NZ608697A/en not_active IP Right Cessation
- 2011-08-26 AR ARP110103116A patent/AR082731A1/es active IP Right Grant
- 2011-08-26 KR KR1020137007666A patent/KR101983979B1/ko active IP Right Grant
- 2011-08-26 RU RU2013113301/04A patent/RU2581362C2/ru not_active IP Right Cessation
- 2011-08-26 PL PL11754836T patent/PL2609086T3/pl unknown
- 2011-08-26 HU HUE11754836A patent/HUE024870T2/en unknown
- 2011-08-26 CA CA2809287A patent/CA2809287C/en not_active Expired - Fee Related
- 2011-08-26 SI SI201130428T patent/SI2609086T1/sl unknown
- 2011-08-26 JP JP2013525189A patent/JP5837934B2/ja not_active Expired - Fee Related
- 2011-08-26 PT PT117548362T patent/PT2609086E/pt unknown
- 2011-08-26 DK DK11754836T patent/DK2609086T3/da active
- 2011-08-26 RS RS20150338A patent/RS54002B1/en unknown
- 2011-08-26 AU AU2011295408A patent/AU2011295408B2/en not_active Ceased
- 2011-08-26 CN CN201180041440.6A patent/CN103189357B/zh not_active Expired - Fee Related
- 2011-08-26 MX MX2013002119A patent/MX342459B/es active IP Right Grant
- 2011-08-26 ES ES11754836.2T patent/ES2537615T3/es active Active
- 2011-08-26 EP EP11754836.2A patent/EP2609086B1/en active Active
- 2011-08-26 BR BR112013004690A patent/BR112013004690A2/pt not_active IP Right Cessation
- 2011-08-26 WO PCT/EP2011/004280 patent/WO2012025239A1/en active Application Filing
-
2012
- 2012-12-24 IL IL223820A patent/IL223820A/en active IP Right Grant
-
2013
- 2013-02-25 CO CO13037611A patent/CO6700825A2/es unknown
- 2013-02-25 CL CL2013000542A patent/CL2013000542A1/es unknown
- 2013-02-26 EC ECSP13012460 patent/ECSP13012460A/es unknown
- 2013-03-26 ZA ZA2013/02265A patent/ZA201302265B/en unknown
- 2013-11-13 HK HK13112723.4A patent/HK1185346A1/xx not_active IP Right Cessation
-
2015
- 2015-03-31 CY CY20151100316T patent/CY1116158T1/el unknown
- 2015-05-15 HR HRP20150520TT patent/HRP20150520T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
CO6700824A2 (es) | 2-oxi-quinolina-3- carboxamidas sustituidas como moduladores kcnq2/3 | |
PA8848201A1 (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes | |
UY33245A (es) | Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas | |
NZ716840A (en) | Combination formulation of two antiviral compounds | |
BR112014000792A2 (pt) | compostos de piperidinila para uso como inibidores da tanquirase | |
CU24187B1 (es) | Derivados sustituidos de imidazopiridazinas útiles para el tratamiento o profilaxis de trastornos hiperproliferativos y la angiogénesis | |
UY33238A (es) | "Compuestos en calidad de antagonistas de bradiquinina-b1" | |
CL2012001821A1 (es) | Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
SV2008003045A (es) | Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes | |
UY33241A (es) | ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?. | |
UY33246A (es) | Tienopirimidinas que contienen cicloalquilo para composiciones farmacéuticas | |
CO6351738A2 (es) | Compuestos organicos | |
ECSP13012573A (es) | 6-amino-nicotinamidas sustituidas como moduladores de KCNQ2/3 | |
CO6700825A2 (es) | 2-oxo-y 2-tioxo-dihidroquinolinas-3-carboxamidas sustituidos como ,oduladores kcnq2/3 | |
BR112012030482A2 (pt) | tratamento de diabetes tipo 2 | |
MX337320B (es) | Análogos halogenados de agentes anti-fibroticos. | |
BR112017005242A2 (pt) | composto, composição farmacêutica, e, composto para uso. | |
PH12016501932A1 (en) | Amido-substituted azole compounds | |
BR112015015515A2 (pt) | composições fungicidas sinérgicas | |
BR112015018047A2 (pt) | composições estáveis que compreendem heparinoide, anestésico de ação aguda e tampão | |
MX2017009849A (es) | Composiciones de profármaco de monometilfumarato. | |
CO6341625A2 (es) | Derivados de indol como agentes anticáncer | |
EA200602049A1 (ru) | Пролекарства стероидов с андрогенным действием | |
CY1118552T1 (el) | Νεα παραγωγα πυριμιδινης ως αναστολεις φωσφοδιεστερασης 10 (pde-10) |